Zobrazeno 1 - 10
of 80
pro vyhledávání: '"Paul Cool"'
Autor:
William Cross, Iben Lyskjær, Tom Lesluyes, Steven Hargreaves, Anna-Christina Strobl, Christopher Davies, Sara Waise, Shadi Hames-Fathi, Dahmane Oukrif, Hongtao Ye, Fernanda Amary, Roberto Tirabosco, Craig Gerrand, Toby Baker, David Barnes, Christopher Steele, Ludmil Alexandrov, Gareth Bond, Genomics England Research Consortium, Paul Cool, Nischalan Pillay, Peter Van Loo, Adrienne M. Flanagan
Publikováno v:
Genome Medicine, Vol 14, Iss 1, Pp 1-12 (2022)
Abstract Background Central conventional chondrosarcoma (CS) is the most common subtype of primary malignant bone tumour in adults. Treatment options are usually limited to surgery, and prognosis is challenging. These tumours are characterised by the
Externí odkaz:
https://doaj.org/article/ffacb8a0eb7048c79fcc4c60653e1002
Autor:
Katie A. Hoban, BSc (Hons), MBChB, MSc, MRCS (Glasg), Samantha Downie, BMedSci (Hons), MBChB, MRCS (Ed), Douglas J.A. Adamson, MBChB, MD, PhD, FRCP (Edin), FRCR, James G. MacLean, MBChB, FRCS, FRSEd T&O, Paul Cool, MD, MMedSc(Res), DipStat, FRCS(Ed), FRCD(Orth), Arpit C. Jariwala, MS Orth, MCh Orth Dundee, MRCS Ed, FRCSEd T&O, MD
Publikováno v:
JSES International, Vol 6, Iss 4, Pp 675-681 (2022)
Hypothesis: The aim of this study was to investigate the reproducibility, reliability, and accuracy of Mirels’ score in upper limb bony metastatic disease and validate its use in predicting pathologic fractures. Methods: Forty-five patients with up
Externí odkaz:
https://doaj.org/article/5826fc9b0db54848a9189393bf601b43
Autor:
Iben Lyskjær, Christopher Davies, Anna‐Christina Strobl, Joanna Hindley, Steven James, Radhesh K. Lalam, William Cross, Geoff Hide, Kenneth S. Rankin, Lee Jeys, Roberto Tirabosco, Jonathan Stevenson, Genomics England Research Consortium, Paul O’Donnell, Paul Cool, Adrienne M. Flanagan
Publikováno v:
Molecular Oncology, Vol 15, Iss 12, Pp 3679-3690 (2021)
Chondrosarcoma (CS) is a rare tumour type and the most common primary malignant bone cancer in adults. The prognosis, currently based on tumour grade, imaging and anatomical location, is not reliable, and more objective biomarkers are required. We ai
Externí odkaz:
https://doaj.org/article/06050dfe09da4f93b0994c5d65b4ce29
Autor:
Debashis Dass, Eamon Ramhamadany, Siddarth Govilkar, John-Henry Rhind, David Ford, Rohit Singh, Geraint Thomas, Paul Cool
Publikováno v:
Journal of Emergencies, Trauma and Shock, Vol 14, Iss 2, Pp 75-79 (2021)
Introduction: On June 24 in the United Kingdom, there were 277,989 cases of COVID-19 and 39,369 deaths recorded. The government enforced a complete lockdown on March 23 that resulted in cessation of all elective admissions on 24th onward, with only a
Externí odkaz:
https://doaj.org/article/de24a88bfaa443b48a32228ce43a84f2
Autor:
Christine Eiser, Paul Cool, Robert J. Grimer, Simon R. Carter, Imogen M. Cotter, Ann J. Ellis, Sheryl Kopel
Publikováno v:
Sarcoma, Vol 1, Iss 1, Pp 39-45 (1997)
Purpose. We report on the quality of life following treatment for a malignant primary bone tumour around the knee in skeletally immature children.
Externí odkaz:
https://doaj.org/article/30a3533ce5994e7cbb06a7b637cf04b4
Publikováno v:
Sarcoma, Vol 1, Iss 2, Pp 75-77 (1997)
Externí odkaz:
https://doaj.org/article/56a737bf2140413399c2cbb0cd7af7d7
Publikováno v:
Cureus.
Autor:
Paul O'Donnell, Radhesh K Lalam, Steven James, Geoff Hide, Christopher Davies, Roberto Tirabosco, Jonathan Stevenson, Adrienne M. Flanagan, Paul Cool, Iben Lyskjaer, Joanna Hindley, Lee Jeys, William Cross, Anna-Christina Strobl, Kenneth S. Rankin
Publikováno v:
Molecular Oncology
Lyskjær, I, Davies, C, Strobl, A C, Hindley, J, James, S, Lalam, R K, Cross, W, Hide, G, Rankin, K S, Jeys, L, Tirabosco, R, Stevenson, J, O’Donnell, P, Cool, P, Flanagan, A M & Genomics England Research Consortium 2021, ' Circulating tumour DNA is a promising biomarker for risk stratification of central chondrosarcoma with IDH1/2 and GNAS mutations ', Molecular Oncology . https://doi.org/10.1002/1878-0261.13102
Molecular Oncology, Vol 15, Iss 12, Pp 3679-3690 (2021)
Lyskjær, I 2021, ' Circulating tumour DNA is a promising biomarker for risk stratification of central chondrosarcoma with IDH1/2 and GNAS mutations ', Molecular Oncology . https://doi.org/10.1002/1878-0261.13102
Lyskjær, I, Davies, C, Strobl, A C, Hindley, J, James, S, Lalam, R K, Cross, W, Hide, G, Rankin, K S, Jeys, L, Tirabosco, R, Stevenson, J, O’Donnell, P, Cool, P, Flanagan, A M & Genomics England Research Consortium 2021, ' Circulating tumour DNA is a promising biomarker for risk stratification of central chondrosarcoma with IDH1/2 and GNAS mutations ', Molecular Oncology . https://doi.org/10.1002/1878-0261.13102
Molecular Oncology, Vol 15, Iss 12, Pp 3679-3690 (2021)
Lyskjær, I 2021, ' Circulating tumour DNA is a promising biomarker for risk stratification of central chondrosarcoma with IDH1/2 and GNAS mutations ', Molecular Oncology . https://doi.org/10.1002/1878-0261.13102
Chondrosarcoma (CS) is a rare tumour type and the most common primary malignant bone cancer in adults. The prognosis, currently based on tumour grade, imaging and anatomical location, is not reliable, and more objective biomarkers are required. We ai
Autor:
Paul Cool, Stuart Hay, Robert W Jordan, Manikandar Srinivas Cheruvu, Georgios Orfanos, Gopikanthan Manoharan
Publikováno v:
Shoulder Elbow
Background Tumour resection followed by joint reconstruction is a surgical option in the appropriate patient. The evidence for such reconstructive surgery of the elbow joint is limited. The aim of this study is to review the literature to evaluate th
Autor:
Paul Cool, David Ford, John-Henry Rhind, Debashis Dass, Rohit Singh, Siddarth Govilkar, Eamon Ramhamadany, Geraint Thomas
Publikováno v:
Journal of Emergencies, Trauma and Shock, Vol 14, Iss 2, Pp 75-79 (2021)
Journal of Emergencies, Trauma, and Shock
Journal of Emergencies, Trauma, and Shock
Introduction: On June 24 in the United Kingdom, there were 277,989 cases of COVID-19 and 39,369 deaths recorded. The government enforced a complete lockdown on March 23 that resulted in cessation of all elective admissions on 24th onward, with only a